Sandu Pharma.

Sandu_Pharma.03 May 2024

Pharmaceuticals

₹

+0.60 (+0.98%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Sandu Pharma.

Sandu Pharma.

Pharmaceuticals

Sandu_Pharma.03 May 2024

₹

+0.60 (+0.98%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
12-Aug-2023	D	Board approved dividend Board of Director at their Meeting Held on 14th August 2023 has recommended Dividend at the rate of Rs 0.75 paisee per Equity Shares (i.e 7.5 percent on paid up share Capital of the Company for the Financial Year ended 31st March 2023 ,subject to approval of the final dividend by the Shareholders at the 37th Annual General Meeting. We further would like to inform you that Rest all the items mentioned in the Outcome of the Meeting remains unchanged. You are requested to kindly take the same on record. Intimation about the book closure and record date (As Per BSE Announcement dated on 14.08.2023)	18-Sep-2023
12-Aug-2022	D	Outcome of the Board Meeting Recommended Dividend of Rs 0.75 Paisee/- per Equity Shares(i.e 0.75% on paid up Share Capital of the Company) having face value of Rs 10/- each for the Financial Year ended 31st March 2022,upon approval of the final dividend by the Shareholders at the 37th Annual General Meeting, the dividend amount after deducting applicable TDS, will be credited to the Bank Accounts of the Shareholders who have registered their Bank Account details with the Depository/ Company and for those Shareholders who have not registered their Bank Account details, dividend warrants will be dispatched on or before 25th October 2022. Board has recommended Dividend at the rate of Rs 0.75 paisee per Equity Shares (i.e 7.5 percent on paid up share Capital of the Company for the Financial Year ended 31st March 2022,subject to approval of the final dividend by the Shareholders at the 37th Annual General Meeting, which was inadvertently due to clerical mistake was mentioned as 0.75percent instead of 7.5 percent to paid up capital of the Company. (As Per BSE Bulletin Dated on 29.08.2022) Intimation about Record Date The Record Date for determining the members eligible to receive the aforesaid dividend will be 23rd September 2022. (As per BSE Announcement Dated on 12/08/2022) Revised Outcome of the Board Meeting with Scrip Code 524703 in respect of the Dividend (As Per BSE Announcement Dated 29.08.2022)	23-Sep-2022
14-Aug-2021	D	Corporate Action Board Approves Dividend	22-Sep-2021
14-Aug-2023	BC	change in directorate	01-Apr-2024
12-Apr-2024	BC	Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement Regulation 2015-Minor Errata in Disclosure given on 30th March 2024 Outcome of the Board Meeting dated 30th March 2024 (As P	01-Apr-2024
30-Mar-2024	BC	Outcome of the Board Meeting dated 30th March 2024 Retirement of Non Executive Independent Directors on the completion of 02nd term of 05 years	31-Mar-2024
20-Mar-2024	BC	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/03/2024 inter alia to consider and approve 1. To Consider and Appoint Chief Fin	30-Mar-2024
30-Mar-2024	BC	Outcome of the Board Meeting dated 30th March 2024	30-Mar-2024

No Rights has been declared by Sandu_Pharma.

Book Closure

Record Date	Split Date	Purpose
01-Apr-2024	-	change in directorate
01-Apr-2024	-	Regulation 30 of SEBI (Listing Obligation and Disclosure Requirement Regulation 2015-Minor Errata in Disclosure given on 30th March 2024 Outcome of the Board Meeting dated 30th March 2024 (As P
31-Mar-2024	-	Outcome of the Board Meeting dated 30th March 2024 Retirement of Non Executive Independent Directors on the completion of 02nd term of 05 years
30-Mar-2024	-	SANDU PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/03/2024 inter alia to consider and approve 1. To Consider and Appoint Chief Fin
30-Mar-2024	-	Outcome of the Board Meeting dated 30th March 2024

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Sandu Pharmaceuticals Ltd ₹61.60(+0.60/0.98%)	61.60	+0.60	58.93	9.24	51.69	1.88
Astrazeneca Pharma India Ltd ₹5,417.95(+84.10/1.58%)	5,417.95	+84.10	13,334.63	67.79	83.60	20.36
Bliss GVS Pharma Ltd ₹119.05(-10.15/-7.86%)	119.05	-10.15	1,352.61	67.42	19.82	1.38
Cipla Ltd ₹1,421.95(+2.40/0.17%)	1,421.95	+2.40	114,613.75	54.95	34.85	4.43
Amrutanjan Health Care Ltd ₹777.35(-9.25/-1.18%)	777.35	-9.25	2,274.11	29.81	51.68	8.68
Abbott India Ltd ₹26,142.70(-461.65/-1.74%)	26,142.70	-461.65	56,534.24	18.89	49.35	18.18

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	17.43	16.61	17.66	15.26	17.09	16.76
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	17.43	16.61	17.66	15.26	17.09	16.76
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.03	0.09	0.00	0.04	0.03	0.17
Total Income	17.46	16.69	17.66	15.31	17.12	16.93
Total Expenditure	16.92	15.78	17.30	14.78	16.27	15.90
PBIDT	0.54	0.91	0.36	0.53	0.85	1.03
Interest	0.02	0.01	0.02	0.02	0.02	0.02
PBDT	0.52	0.90	0.33	0.51	0.83	1.01
Depreciation	0.14	0.13	0.12	0.13	0.13	0.13
Tax	0.11	0.21	0.06	0.10	0.20	0.27
Deferred Tax	0.06	0.00	0.04	0.00	0.02	0.01
Reported Profit After Tax	0.21	0.55	0.11	0.27	0.48	0.60
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.21	0.55	0.11	0.27	0.48	0.60

EPS (Unit Curr.)	0.21	0.57	0.11	0.27	0.52	0.64
EPS (Adj) (Unit Curr.)	0.21	0.57	0.11	0.27	0.52	0.64
Calculated EPS (Unit Curr.)	0.21	0.57	0.11	0.28	0.50	0.62
Calculated EPS (Adj) (Unit Curr.)	0.21	0.57	0.11	0.28	0.50	0.62
Calculated EPS (Ann.) (Unit Curr.)	0.86	2.28	0.45	1.13	2.00	2.48
Calculated EPS (Adj) (Ann.) (Unit Curr.)	0.86	2.28	0.45	1.13	2.00	2.48
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	9.66	9.66	9.66	9.66	9.66	9.66
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	3.10	5.48	2.04	3.47	4.97	6.15
PBDTM(%)	2.98	5.42	1.87	3.34	4.86	6.03
PATM(%)	1.20	3.31	0.62	1.77	2.81	3.58

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	17.43	16.61	17.66	15.26	17.09	16.76
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	17.43	16.61	17.66	15.26	17.09	16.76
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.03	0.09	0.00	0.04	0.03	0.17
Total Income	17.46	16.69	17.66	15.31	17.12	16.93
Total Expenditure	16.92	15.78	17.30	14.78	16.27	15.90
PBIDT	0.54	0.91	0.36	0.53	0.85	1.03
Interest	0.02	0.01	0.02	0.02	0.02	0.02
PBDT	0.52	0.90	0.33	0.51	0.83	1.01
Depreciation	0.14	0.13	0.12	0.13	0.13	0.13
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.11	0.21	0.06	0.10	0.19	0.27
Deferred Tax	0.06	0.00	0.04	0.00	0.02	0.01
Reported Profit After Tax	0.21	0.55	0.11	0.27	0.48	0.60
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	0.21	0.55	0.11	0.27	0.48	0.60

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.21	0.55	0.11	0.27	0.48	0.60

EPS (Unit Curr.)	0.21	0.57	0.11	0.26	0.51	0.64
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	9.66	9.66	9.66	9.66	9.66	9.66

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	3.10	5.48	2.04	3.47	4.97	6.15
PBDTM(%)	2.98	5.42	1.87	3.34	4.86	6.03
PATM(%)	1.20	3.31	0.62	1.77	2.81	3.58

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	9.66	8.81	7.92	7.08	7.08	7.08
Reserves Total	29.58	27.22	24.67	22.16	21.71	21.00
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.44	0.90	0.00	0.00	0.00
Total Shareholders Funds	39.24	36.47	33.49	29.24	28.79	28.08
Secured Loans	0.00	0.00	0.02	1.25	6.17	9.42
Unsecured Loans	0.00	0.00	0.00	0.00	0.00	0.00
Total Debt	0.00	0.00	0.02	1.25	6.17	9.42
Total Liabilities	39.24	36.47	33.51	30.49	34.96	37.50
APPLICATION OF FUNDS :
Gross Block	27.51	26.38	26.02	25.89	25.78	25.67
Less : Accumulated Depreciation	10.89	10.37	9.84	9.29	8.73	8.10
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	16.62	16.01	16.18	16.60	17.05	17.57
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.42	0.48	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	9.66	9.11	0.24	0.82	1.13	1.12
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	14.33	11.27	11.14	14.36	13.26	11.44
Sundry Debtors	4.79	3.99	5.35	4.68	4.80	6.69
Cash and Bank	2.29	4.17	11.66	1.54	0.79	1.41
Loans and Advances	4.13	4.21	2.40	1.83	1.24	1.30
Total Current Assets	25.54	23.65	30.54	22.42	20.08	20.84
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	9.81	7.89	7.77	6.91	5.28	4.11
Provisions	4.07	3.98	4.73	3.18	2.58	2.11
Total Current Liabilities	13.88	11.87	12.50	10.09	7.86	6.21
Net Current Assets	11.65	11.78	18.04	12.33	12.21	14.63
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.04	0.02	0.00
Deferred Tax Liability	1.04	0.94	0.95	0.88	0.83	0.82
Net Deferred Tax	-1.04	-0.94	-0.95	-0.84	-0.81	-0.82
Total Assets	37.31	36.43	33.50	28.91	29.57	32.50
Contingent Liabilities	3.37	2.83	2.83	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.94	4.53	1.22	0.74	1.41
Net Cash from Operating Activities	0.22	0.95	7.59	6.20	3.74
Net Cash Used In Investing Activities	0.53	-5.47	-5.58	-0.37	-0.10
Net Cash Used In Financing Activities	0.58	0.93	1.30	-5.36	-4.26
Net Inc./Dec In Cash And Cash Equivalents	1.33	-3.59	3.31	0.48	-0.62
Cash And Cash Equivalents At End Of The Year	2.27	0.94	4.53	1.22	0.79

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

42.90%

FII Shareholding

0.00%

DII Shareholding

0.01%

Public Shareholding

57.09%

**Promoter pledged shareholding 42.90%

About Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 58.93 crores. It has reported a sales of Rs. 17.43 crores and a net profit of Rs. 0.21 crores for the quarter ended December 2018. The company management includes K Vinay Kumar, Dilip R Salgaocar,Krishna B Deshpande,Madan Laxman Kapre,K Vinay Kumar,Shashank B Sandu,Umesh B Sandu,Shubhada P Sandu,Pratika Mhambray (Sandu Pharmaceuticals Ltd) among others.

Chairman

K Vinay Kumar

Registered office

Plot No 25/26/29 & 30,Pilerne Indl Estate Marra Bard,Bardez,Goa,403511

FAX :

Background

Incorporation Year1985

Face Value₹10

Market Lot1

How to buy Sandu Pharma. shares on nse?

To buy Sandu Pharma. shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Sandu Pharma. share price today?

The Sandu Pharma. shares price on nse is Rs.61.6 today.

What is the market cap of Sandu Pharma. shares on BSE ?

The company has a market capitalization of Rs.58.93Cr

What is the PE & PB ratio of Sandu Pharma. shares ?

PE is 51.69 and PB is 1.88

What is the 52 Week High and Low of Sandu Pharma. shares?

Sandu Pharma. stock price high: Rs.85 Sandu Pharma. stock price low: Rs.49